Synthesis and SAR of Thiazolylmethylphenyl Glucoside as Novel C-Aryl Glucoside SGLT2 Inhibitors
- PMID: 24900297
- PMCID: PMC4018110
- DOI: 10.1021/ml100256c
Synthesis and SAR of Thiazolylmethylphenyl Glucoside as Novel C-Aryl Glucoside SGLT2 Inhibitors
Abstract
Novel C-aryl glucoside SGLT2 inhibitors containing the thiazole motif were designed and synthesized for biological evaluation. Among the compounds assayed, thiazole containing furanyl moiety 14v and thiophenyl moiety 14y demonstrated the best in vitro inhibitory activity against SGLT2 in this series to date (IC50 = 0.720 nM for 14v and IC50 = 0.772 nM for 14y). Both of these compounds have been further evaluated on a urinary glucose excretion test and the urine volumes excreted.
Keywords: SAR; SGLT2; Thiazole; diabetes; glucoside.
Figures



Similar articles
-
Exploration of SAR regarding glucose moiety in novel C-aryl glucoside inhibitors of SGLT2.Bioorg Med Chem Lett. 2011 Jan 15;21(2):742-6. doi: 10.1016/j.bmcl.2010.11.115. Epub 2010 Dec 3. Bioorg Med Chem Lett. 2011. PMID: 21193308
-
Pyrimidinylmethylphenyl glucoside as novel C-aryl glucoside SGLT2 inhibitors.Bioorg Med Chem Lett. 2010 Dec 1;20(23):7046-9. doi: 10.1016/j.bmcl.2010.09.103. Epub 2010 Sep 29. Bioorg Med Chem Lett. 2010. PMID: 20952196
-
Novel C-aryl glucoside SGLT2 inhibitors as potential antidiabetic agents: Pyridazinylmethylphenyl glucoside congeners.Bioorg Med Chem Lett. 2010 Jun 1;20(11):3420-5. doi: 10.1016/j.bmcl.2010.04.006. Epub 2010 Apr 9. Bioorg Med Chem Lett. 2010. PMID: 20434909
-
Recent Developments of C-Aryl Glucoside SGLT2 Inhibitors.Curr Med Chem. 2016;23(8):832-49. doi: 10.2174/0929867323666160210125747. Curr Med Chem. 2016. PMID: 26861002 Review.
-
Design of SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: A History Driven by Biology to Chemistry.Med Chem. 2015;11(4):317-28. doi: 10.2174/1573406411666150105105529. Med Chem. 2015. PMID: 25557661 Review.
Cited by
-
Thiazole: A Versatile Standalone Moiety Contributing to the Development of Various Drugs and Biologically Active Agents.Molecules. 2022 Jun 21;27(13):3994. doi: 10.3390/molecules27133994. Molecules. 2022. PMID: 35807236 Free PMC article. Review.
-
Sympatholytic Mechanisms for the Beneficial Cardiovascular Effects of SGLT2 Inhibitors: A Research Hypothesis for Dapagliflozin's Effects in the Adrenal Gland.Int J Mol Sci. 2021 Jul 19;22(14):7684. doi: 10.3390/ijms22147684. Int J Mol Sci. 2021. PMID: 34299304 Free PMC article.
References
-
- International Diabetes Federation. Diabetes Atlas, 4th ed.; International Diabetes Federation: Montreal, Canada, 2009.
-
- Dwarakanathan A. Diabetes update. J. Insur. Med. 2006, 38, 20–30. - PubMed
-
- Mackenzie B.; Loo D. D.; Panayotova-Heiermann M.; Wright E. M. Biophysical characteristics of the pig kidney Na+/glucose cotransporter SGLT2 reveal a common mechanism for SGLT1 and SGLT2. J. Biol. Chem. 1996, 271, 32678–32683. - PubMed
-
- Moe O. W.; Berry C. A.; Rector F. C.. The Kidney, 5th ed.; Brenner B. M., Rector F. C., Eds.; WB Saunders Co.: Philadelphia, PA, 2000; pp 375−415.
-
- Washburn W. Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents. Expert Opin. Ther. Patents 2009, 25, 1485–1499. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Miscellaneous